Trials & Filings

Janssen NDA for FDC Receives CRL

Agency wants more data on Invokana dosing regimens

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Janssen Research & Development, LLC, a Johnson & Johnson subsidiary, has received from a complete response letter (CRL) from the FDA regarding its NDA for a fixed-dose combination (FDC) of canagliflozin and immediate-release metformin to treat adults with type 2 diabetes. The CRL requested additional information to support the comparability of the twice-daily dosing regimen of canagliflozin — as part of the canagliflozin and metformin FDC — and the once-daily dosing of canag...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters